Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, and hanging with a visiting short person. We also hope to have time for our weekly listening party, where the rotation will likely include this, this, this, this and this. And what about you? As noted previously, this is a marvelous time to enjoy the great outdoors. City streets beckon. And beaches and woodsy trails are closer than you think. You could also curl up with a good book if the weather fails to cooperate, tidy around your castle, or get a head start on back-to-school shopping — the economy could always use a boost. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

The U.S. Food and Drug Administration approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.S. regulators using a more sensitive measure of remission, STAT explains. The drug, which will be sold under the brand name Zenbexus, is part of a Bristol research effort to develop a new and more potent class of blood cancer drugs called CELMoDs that work by redirecting a cell’s natural machinery to eliminate cancer-causing proteins.

A U.S. appeals court ruled that a lower-court judge ‌erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, Reuters writes. In a 3-0 decision, the appeals court decided UMB Bank was entitled to represent Celgene shareholders as a trustee despite ​an error in how it was appointed. The case arose from Bristol Myers’ purchase of Celgene for $80.3 billion in 2019. Celgene shareholders who ​held “contingent value rights” were entitled to an extra $9 per share in cash if Bristol Myers won timely ​U.S. regulatory approvals for three drugs.

Continue to STAT+ to read the full story…

​Read More

Published

on

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, and hanging with a visiting short person. We also hope to have time for our weekly listening party, where the rotation will likely include this, this, this, this and this. And what about you? As noted previously, this is a marvelous time to enjoy the great outdoors. City streets beckon. And beaches and woodsy trails are closer than you think. You could also curl up with a good book if the weather fails to cooperate, tidy around your castle, or get a head start on back-to-school shopping — the economy could always use a boost. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

The U.S. Food and Drug Administration approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.S. regulators using a more sensitive measure of remission, STAT explains. The drug, which will be sold under the brand name Zenbexus, is part of a Bristol research effort to develop a new and more potent class of blood cancer drugs called CELMoDs that work by redirecting a cell’s natural machinery to eliminate cancer-causing proteins.

A U.S. appeals court ruled that a lower-court judge ‌erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, Reuters writes. In a 3-0 decision, the appeals court decided UMB Bank was entitled to represent Celgene shareholders as a trustee despite ​an error in how it was appointed. The case arose from Bristol Myers’ purchase of Celgene for $80.3 billion in 2019. Celgene shareholders who ​held “contingent value rights” were entitled to an extra $9 per share in cash if Bristol Myers won timely ​U.S. regulatory approvals for three drugs.

Continue to STAT+ to read the full story…

​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read